Yuyu Pharma (000220) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Yuyu Pharma KRW 11,085, price KRW 3,695, upside +200.0%, quality 62 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Yuyu Pharma for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range 3,510 KRW – 10,726 KRW · fair‑value band 8,191 KRW – 13,858 KRW · the 3,695 KRW price screens below the 11,085 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Yuyu Pharma in your weekly email
Every Wednesday you see whether Yuyu Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Yuyu Pharma, Inc. develops and markets pharmaceutical products in Korea and United States. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc.
Show more
Yuyu Pharma, Inc. develops and markets pharmaceutical products in Korea and United States. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc. was founded in 1941 and is headquartered in Jecheon-si, South Korea.
Stock analysis
Yuyu Pharma (000220) currently trades at 3,695 KRW, while our model-based Fair Value estimate is 11,085 KRW, implying the stock looks roughly 66.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 12,049 KRW per share, and 22 of the 24 models we run sit above the 3,695 KRW price.
Bear case: the Earnings-Based group reads lowest at 3,521 KRW, and 2 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: 8,191 KRW (bear) to 13,858 KRW (bull), the price of 3,695 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Yuyu Pharma reported revenue of 141B KRW in FY2025 versus 116B KRW in FY2021, a compound +5.1%/yr. Reported net income was 8.2B KRW in FY2025.
Key figures
Market cap 58.2B KRW (≈ $42.8M) · P/S ratio 0.40 · Dividend yield 3.1% · Net margin 5.8% · Return on equity 6.8% · Return on assets (EBIT) 2.4% · Operating margin 12.1% · Revenue (TTM) 144B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 22% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 200%, 000220 screens cheaper than that median.
Fair Value models
Bear 8,191 KRWFair Value 11,085 KRWBull 13,858 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.70/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.5%
Start year 2020 (pandemic). Over 10 years: +7.3% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+19.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+16.3%
Dividend (yield on the price)3.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.16.3% vs −6.7%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 8%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−9.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −11.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 621 stocks
Beats the industry median on 8/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score62 · Above median
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (TTM)6.8% · Above median
Return on assets3.4% · Above median
Net margin (TTM)6.3% · Below median
Operating margin (TTM)12.1% · Above median
Growth and dividend
Revenue growth8.0% · Above median
Dividend yield (TTM)3.1% · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Yuyu Pharma Fair Value". https://www.fairvalue-calculator.com/stock/000220
Frequently asked questions
Is Yuyu Pharma (000220) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of 11,085 KRW versus a price of 3,695 KRW, about +200% upside (undervalued).
What is the fair value of 000220?
Our model-based fair value for Yuyu Pharma is 11,085 KRW (as of Sep 27, 2026), built from audited fundamentals. The current price: 3,695 KRW.
What is the quality score of 000220?
Yuyu Pharma has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Yuyu Pharma (000220)?
Our model-based price target is the fair value of 11,085 KRW (as of Sep 27, 2026) from 24 valuation models. Cautious scenario 8,191 KRW, optimistic scenario 13,858 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Yuyu Pharma stock forecast for 2026?
Our models put fair value at 11,085 KRW, about +200% upside versus a price of 3,695 KRW (undervalued). Cautious scenario 8,191 KRW, optimistic scenario 13,858 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Yuyu Pharma (000220)?
Yuyu Pharma reported trailing-twelve-month revenue of about 144B KRW (latest available figure, as of Sep 27, 2026).
Does Yuyu Pharma pay a dividend?
Yuyu Pharma currently shows a dividend yield of about 3.11% relative to its recent price (as of Sep 27, 2026).
What growth is priced into Yuyu Pharma (000220)?
For today's price to be fair in a discounted-cash-flow model, Yuyu Pharma would have to grow free cash flow by -9.8 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.5 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of 000220 use?
Our models discount Yuyu Pharma at 8.9 %: a base by market capitalisation (nano), damped by beta 0.36, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Yuyu Pharma that is -9.8 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Yuyu Pharma (000220) delivered so far?
Over the past 5 years revenue at Yuyu Pharma grew +7.5 % a year. The price currently implies -9.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Yuyu Pharma (000220) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Yuyu Pharma (-9.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Yuyu Pharma (000220)?
The free-cash-flow yield on the price is 12.76 %: that much free cash flow Yuyu Pharma produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Yuyu Pharma (000220)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Yuyu Pharma it is 11,085 KRW per share (as of Sep 27, 2026), against a price of 3,695 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Yuyu Pharma stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 000220 trades below its calculated fair value: price 3,695 KRW, fair value 11,085 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 000220?
No. The price is what the market pays today (3,695 KRW); the fair value is what the company's own numbers justify (11,085 KRW). For Yuyu Pharma the two are 7,390 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Yuyu Pharma worth?
The market values Yuyu Pharma at about 58.2B KRW (market capitalisation, as of Sep 27, 2026). Per share that is 3,695 KRW; our models calculate a fair value of 11,085 KRW per share.
What do the bullish and bearish scenarios say about 000220?
Our models span a range for Yuyu Pharma: cautious scenario 8,191 KRW, base 11,085 KRW, optimistic 13,858 KRW per share (as of Sep 27, 2026, price 3,695 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Yuyu Pharma (000220)?
Balance-sheet figures for Yuyu Pharma (as of Sep 27, 2026): return on equity 6.8%. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is 000220 from its 52-week high?
Yuyu Pharma trades at 3,695 KRW, about 22% below its 52-week high of 4,740 KRW and 5% above the low of 3,510 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 11,085 KRW is for.
Which stocks are comparable to Yuyu Pharma?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Yuyu Pharma stock attractive at the current price?
The data as of Sep 27, 2026: price 3,695 KRW, calculated fair value 11,085 KRW (+200%), Quality Score 62/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 000220 calculated?
We run Yuyu Pharma through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 11,085 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Yuyu Pharma currently trades 200 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Yuyu Pharma (000220)?
The closing price on Sep 23, 2026 was 3,695 KRW. Our model-based fair value is 11,085 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Yuyu Pharma right now?
The price is below even our cautious bear case (8,191 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (62/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Yuyu Pharma
How large is the market capitalisation of Yuyu Pharma (000220)?
The market capitalisation of Yuyu Pharma is 58.2B KRW (≈ $42.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Yuyu Pharma (000220)?
The price-to-sales ratio of Yuyu Pharma is 0.40 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Yuyu Pharma (000220)?
The dividend yield of Yuyu Pharma is 3.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Yuyu Pharma (000220)?
The net margin of Yuyu Pharma is 5.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Yuyu Pharma (000220)?
The return on equity (ROE) of Yuyu Pharma is 6.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Yuyu Pharma (000220)?
On an EBIT basis the return on assets of Yuyu Pharma is 2.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Yuyu Pharma (000220)?
The operating margin of Yuyu Pharma is 12.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Yuyu Pharma (000220)?
Revenue at Yuyu Pharma is growing +8.0% versus a year earlier (3y avg +0.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Yuyu Pharma (000220)?
Earnings per share at Yuyu Pharma are growing +38.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Yuyu Pharma (000220) carry?
The net debt of Yuyu Pharma is 8.0B KRW (fiscal year 2023, ≈ 1.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Yuyu Pharma in the live analysis
One click puts Yuyu Pharma on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
